Cromos Pharma committed to supporting clinical research into Alzheimer’s disease This September Cromos Pharma is highlighting World Alzheimer’s Month. Alzheimer’s Disease (AD) is the most well-known form of dementia. Dementia is the collective name for progressive brain conditions affecting memory, thinking, behavior and emotions. Dementia affects almost 50 million people worldwide. While aging is a major risk factor for dementia, it also affects people under 65 years. There are over
Getting ready for full implementation of the EU Clinical Trial Regulation The countdown is on for the European Union (EU) Clinical Trial Regulation (Regulation (EU) No 536/2014) (CTR) with a go-live date of 31 January 2022. The implementation of the CTR will bring about significant changes to the way clinical trials are conducted in the EU. In this article Cromos Pharma considers some of the requirements for sponsors. The
Cromos Pharma on rare disease drug development An estimated 475 million people are affected by rare disease worldwide (WEFORUM), and only 5% of people with a rare disease have a treatment. This represents a significant unmet medical need. Rare disease clinical trials involve challenges above and beyond those encountered for large scale clinical studies for more common diseases. Operational and scientific challenges include: Limited pool
